Risk of suicide in users of cardiovascular drugs: A review of the epidemiological evidence

American Journal of Cardiovascular Drugs

Volumn 3, Issue 3, 2003, Pages 163-167

  Jepsen, Peter ^a   Johnsen, Søren P ^a   Sørensen, Henrik T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROPRANOLOL;

CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUICIDE;

EID: 0038236604     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303030-00002     Document Type: Review

References (30)

1. Waal HJ. Propranolol-induced depression (letter). BMJ 1967; 2 (543): 50
2. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986 Jan 17; 255 (3): 357-60
3. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7 (5): 478-84
4. Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry 1990 Apr; 35 (3): 257-9
5. Biriell C, McEwen J, Sanz E . Depression associated with diltiazem (letter). BMJ 1989 ; 299 (6702): 796
6. Patten SB, Williams JV, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996 Sep; 41 (7): 469-76
7. Dunn NR, Freemantle SN, Mann RD. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol 1999 Aug; 48 (2): 230-3
8. Lindberg G, Bingefors K, Ranstam J, et al. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ 1998 Mar 7; 316 (7133): 741-5
9. Sørensen HT, Mellemkjær L, Olsen JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2001 Sep; 52 (3): 313-8
10. Hullett FJ, Potkin SG, Levy AB, et al. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988 Oct; 145 (10): 1277-9
11. Dassylva B. Verapamil may cause depression. Can J Psychiatry 1993 May; 38 (4): 299-300
12. McAllister-Williams RH. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990 Oct; 157: 618-9
13. bergman U, Isacsson G. Use of calcium channel blockers and risk of suicide: independent studies are needed before causality is established (letter). BMJ 1998; 317 (7165): 1076
14. Wiholm BE, Sundstrom A, Altredsson L. Use of calcium channel blockers and risk of suicide: drug prescriptions over longer period should have been followed up. BMJ 1998 Oct 17; 317 (7165): 1076-7
15. Chen YT, Makuch RW. Use of calcium channel blockers and risk of suicide: prescriptions for particular drug are influenced by numerous factors (letter). BMJ 1998; 317 (7165): 1077
16. Gasse C, Derby LE, Vasilakis C, et al. Risk of suicide among users of calcium channel blockers: population based, nested case-control study (short report). BMJ 2000; 320 (7244): 1251
17. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 3rd ed. Baltimore: Williams & Wilkins, 1996
18. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1998
19. Olsen JH, Sørensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997 May; 29 (5): 1091-4
20. Stanton AV. Calcium channel blockers: the jury is still out on whether they cause heart attacks and suicide. BMJ 1998 May 16; 316 (7143): 1471-3
21. Ried LD, McFarland BH, Johnson RE, et al. Beta-blockers and depression: the more the murkier? Ann Pharmacother 1998 Jun; 32 (6): 699-708
22. Den Almindelige Danske Lægeforening. Lægeforeningens Medicinfortegnelse. 24th ed. Copenhagen: Lægeforeningens Forlag, 2001
23. Kyvik KO, Stenager EN, Green A, et al. Suicides in men with IDDM. Diabetes Care 1994 Mar; 17 (3): 210-2
24. Lindberg G, Ranstam J, Melander A, et al. Authors reply (letter). BMJ 1998; 317 (7165): 1077
25. Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom 1997; 66 (2): 63-73
26. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 1979 Apr; 47 (2): 343-52
27. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352 (9139): 1498-504
28. Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989 Apr; 13 (4): 656-61
29. Opie LH. Angiotensin-converting enzyme inhibitors: the advance continues. 3rd ed. New York: Authors' Publishing House, 1999
30. Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology (Berl) 1992; 109 (1-2): 12-29